Trends in Cardiovascular Medicine
Volume 16, Issue 3 , Pages 75-80 , April 2006

New Roles for an Old Drug: Inhibition of Gene Expression by Dipyridamole in Platelet–Leukocyte Aggregates

References 

  1. Branger J, van den Blink B, Weijer S, et al. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood. 2003;101:4446–4448
  2. Camera M, Toschi V, Comparato C, et al. Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin. Thromb Haemost. 2002;87:748–755
  3. Carter AB, Monick MM, Hunninghake GW. Both Erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol. 1999;20:751–758
  4. Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke. 2003;34:40–46
  5. Chello M, Mastroroberto P, Malta E, et al. Inhibition by dipyridamole of neutrophil adhesion to vascular endothelium during coronary bypass surgery. Ann Thorac Surg. 1999;67:1277–1282
  6. De La Cruz JP, Blanco E, Sanchez de la Cuesta F. Effect of dipyridamole and aspirin on the platelet–neutrophil interaction via the nitric oxide pathway. Eur J Pharmacol. 2000;397:35–41
  7. Diener HC. Dipyridamole trials in stroke prevention. Neurology. 1998;51:S17–S19
  8. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13
  9. Eisert WG. Dipyridamole. In:  Michelson AD editors. Platelets. San Diego: Academic Press; 2002;p. 803–815
  10. FitzGerald GA. Dipyridamole. N Engl J Med. 1987;316:1247–1257
  11. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2:879–890
  12. Freedman JE, Loscalzo J. Platelet–monocyte aggregates: bridging thrombosis and inflammation. Circulation. 2002;105:2130–2132
  13. Freestone T, Turner RJ, Coady A, et al. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995;15:1145–1151
  14. Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte–platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001;38:1002–1006
  15. Galt SW, Lindemann S, Medd D, et al. Differential regulation of matrix metalloproteinase-9 by monocytes adherent to collagen and platelets. Circ Res. 2001;89:509–516
  16. Giustizieri ML, Albanesi C, Scarponi C, et al. Nitric oxide donors suppress chemokine production by keratinocytes in vitro and in vivo. Am J Pathol. 2002;161:1409–1418
  17. Harding SA, Sommerfield AJ, Sarma J, et al. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis. 2004;176:321–325
  18. Heusinger-Ribeiro J, Fischer B, Goppelt-Struebe M. Differential effects of simvastatin on mesangial cells. Kidney Int. 2004;66:187–195
  19. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61–67
  20. Ito T, Ikeda U. Inflammatory cytokines and cardiovascular disease. Curr Drug Targets Inflamm Allergy. 2003;2:257–265
  21. Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:656–660
  22. Kopp CW, Steiner S, Nasel C, et al. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting. Stroke. 2003;34:2560–2567
  23. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739–746
  24. Lehr HA, Weyrich AS, Saetzler RK, et al. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. [see comments] J Clin Invest. 1997;99:2358–2364
  25. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  26. Lindemann SW, Weyrich AS, Zimmerman GA. Signaling to translational control pathways: diversity in gene regulation in inflammatory and vascular cells. Trends Cardiovasc Med. 2005;15:9–17
  27. Loftus IM, Naylor AR, Bell PR, Thompson MM. Plasma MMP-9—a marker of carotid plaque instability. Eur J Vasc Endovasc Surg. 2001;21:17–21
  28. Matsumoto M, Einhaus D, Gold ES, Aderem A. Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J Immunol. 2004;172:7377–7384
  29. McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest. 2005;115:538–546
  30. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A. 1996;93:11877–11882
  31. Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104:1533–1537
  32. Minhajuddin M, Fazal F, Bijli KM, et al. Inhibition of mammalian target of rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-kappa B activation in endothelial cells. J Immunol. 2005;174:5823–5829
  33. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  34. Nakagami H, Jensen KS, Liao JK. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med. 2003;35:398–403
  35. Neumann FJ, Marx N, Gawaz M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation. 1997;95:2387–2394
  36. Newman KM, Malon AM, Shin RD, et al. Matrix metalloproteinases in abdominal aortic aneurysm: characterization, purification, and their possible sources. Connect Tissue Res. 1994;30:265–276
  37. Nijm J, Wikby A, Tompa A, et al. Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am J Cardiol. 2005;95:452–456
  38. Nikas SN, Drosos AA. SCIO-469 Scios Inc. Curr Opin Investig Drugs. 2004;5:1205–1212
  39. Okie S. Raising the safety bar—the FDA's coxib meeting. N Engl J Med. 2005;352:1283–1285
  40. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal. 2000;12:1–13
  41. Pargellis C, Regan J. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr Opin Investig Drugs. 2003;4:566–571
  42. Pietersma A, Tilly BC, Gaestel M, et al. p38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level. Biochem Biophys Res Commun. 1997;230:44–48
  43. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641–1649
  44. Rekhter MD. Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc Res. 1999;41:376–384
  45. Rekhter MD, O'Brien E, Shah N, et al. The importance of thrombus organization and stellate cell phenotype in collagen I gene expression in human, coronary atherosclerotic and restenotic lesions. Cardiovasc Res. 1996;32:496–502
  46. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  47. Riksen NP, Oyen WJ, Ramakers BP, et al. Oral therapy with dipyridamole limits ischemia–reperfusion injury in humans. Clin Pharmacol Ther. 2005;78:52–59
  48. Rivey MP, Alexander MR, Taylor JW. Dipyridamole: a critical evaluation. Drug Intell Clin Pharm. 1984;18:869–880
  49. Rudic RD, Brinster D, Cheng Y, et al. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res. 2005;96:1240–1247
  50. Sarma J, Laan CA, Alam S, et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation. 2002;105:2166–2171
  51. Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med. 2004;36:98–118
  52. Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis. 2002;160:91–102
  53. Smyth SS, Reis ED, Zhang W, et al. Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation. 2001;103:2501–2507
  54. Tailor A, Granger DN. Hypercholesterolemia promotes leukocyte-dependent platelet adhesion in murine postcapillary venules. Microcirculation. 2004;11:597–603
  55. Taniguchi M, Magata S, Suzuki T, et al. Dipyridamole protects the liver against warm ischemia and reperfusion injury. J Am Coll Surg. 2004;198:758–769
  56. Topol EJ. Aspirin with bypass surgery–from taboo to new standard of care. N Engl J Med. 2002;347:1359–1360
  57. Vaughan CJ, Gotto AM. Update on statins: 2003. Circulation. 2004;110:886–892
  58. Weksler BB. Antiplatelet agents in stroke prevention. Combination therapy: present and future. Cerebrovasc Dis. 2000;10(Suppl 5):41–48
  59. Weyrich AS, McIntyre TM, McEver RP, et al. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. [see comments] J Clin Invest. 1995;95:2297–2303
  60. Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 1996;97:1525–1534
  61. Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost. 2003;1:1897–1905
  62. Weyrich AS, Denis MM, Kuhlmann-Eyre JR, et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation. 2005;111:633–642
  63. Wung BS, Cheng JJ, Shyue SK, Wang DL. NO modulates monocyte chemotactic protein-1 expression in endothelial cells under cyclic strain. Arterioscler Thromb Vasc Biol. 2001;21:1941–1947
  64. Xiao C, Ghosh S. NF-kappaB, an evolutionarily conserved mediator of immune and inflammatory responses. Adv Exp Med Biol. 2005;560:41–45
  65. Zhang ZG, Zhang L, Tsang W, et al. Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res. 2001;912:181–194
  66. Zimmerman GA. Two by two: the pairings of P-selectin and P-selectin glycoprotein ligand 1. Proc Natl Acad Sci U S A. 2001;98:10023–10024

PII: S1050-1738(05)00236-7

doi: 10.1016/j.tcm.2005.12.002

Trends in Cardiovascular Medicine
Volume 16, Issue 3 , Pages 75-80 , April 2006

Article Tools

* Image Usage & Resolution